Drug intelligence / Profile preview

gallocatechin

Development stage
Preclinical
Lead developer
Sir Run-Run Shaw Hospital
Modality
Small Molecules
Administration
Oral
01

Overview

Gallocatechin is a dietary flavanol (flavan-3-ol) found in green tea and other plant sources. Recent research has identified it as a key metabolite whose deficiency is linked to mesalazine resistance in patients with ulcerative colitis (UC). Gallocatechin acts as an immunomodulator by suppressing the differentiation of pro-inflammatory Th17 cells. Its mechanism involves the activation of the β-catenin/TCF1 signaling pathway, which leads to the upregulation of Suppressor of Cytokine Signaling 3 (SOCS3). This upregulation subsequently inhibits the JAK2/STAT3 signaling cascade and downregulates the expression of the Th17 master transcription factor, RORγt. Preclinical studies in mouse models of colitis have demonstrated that gallocatechin supplementation can reduce colonic inflammation and work synergistically with mesalazine to improve clinical and histological outcomes.

Other names
gallocatechol(2R,3S)-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol
02

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)HNF1A (Hepatocyte nuclear factor 1-alpha)CTNNB1 (Beta-catenin)

Beyond the preview

Go deeper on gallocatechin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gallocatechin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call